NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 18th, at 2:30 pm ET.
Related news for (NGM)
- Federman & Sherwood Announces Investigation Into NeoGames, SA (NASDAQ: NGMS) And Encourages Investors to Contact the Firm
- NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
- NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
- NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
